Ambry Genetics
1 Enterprise
Aliso Viejo, CA 92656
Aliso Viejo, CA – August 25, 2010 – Ambry Genetics, a global leader in genomic services, announced today that it has acquired the Illumina HiSeq 2000 Next Generation Sequencing System as well as received the first 510(K) approved Illumina BeadXpress Genotyping System. Ambry Genetics has been an early adapter of Illumina systems since late 2007 and has extensive experience as a Certified Service Provider. A team of scientists routinely process libraries for all available applications ranging from small RNAs to whole genome DNA sequencing. Ambry has gained a solid reputation for quality data and service as well as flexibility in customizing projects to meet the specific needs of researchers.
The addition of the HiSeq 2000 will allow Ambry Genetics to run large projects for its customers while saving costs and providing the fastest turn-around times for sequencing. Ambry Genetics has an experienced bioinformatics team that can generate custom reports, providing flexible and results-driven informatics for sequencing projects. In addition to sequencing, Ambry Genetics currently offers diverse options for researchers interested in sequence capture / target enrichment by utilizing Agilent Technologies SureSelect, RainDance Technologies and Roche Nimblegen.
The new Illumina BeadXpress adds high-throughput genotyping capabilities to Ambry Genetics existing line of services. The BeadXpress uses GoldenGate assays on the VeraCode technology which provides researchers with accuracy, flexibility and scalability for their projects. The system supports high level variant plexing and can process up to 96 samples per plate, which can dramatically reduce the cost of genotyping assays and deliver rapid turn-around times.
Ambry Genetics, a subsidiary of REALM IDx, Inc., translates scientific research into clinically actionable test results based upon a deep understanding of the human genome and the biology behind genetic disease. It is a leader in genetic testing that aims to improve health by understanding the relationship between genetics and disease. Its unparalleled track record of discoveries over 25 years, and growing database that continues to expand in collaboration with academic, corporate and pharmaceutical partners, means Ambry Genetics is first to market with innovative products and comprehensive analysis that enable clinicians to confidently inform patient health decisions.
Media Contact
Mickie Henshall
Chief Marketing Officer
REALM IDx
mhenshall@realmidx.com